Bardoxolone methyl + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obese Adult Male
Conditions
Obese Adult Male
Trial Timeline
Aug 20, 2019 → Jun 18, 2020
NCT ID
NCT04018339About Bardoxolone methyl + Placebo
Bardoxolone methyl + Placebo is a phase 1 stage product being developed by Kyowa Kirin for Obese Adult Male. The current trial status is completed. This product is registered under clinical trial identifier NCT04018339. Target conditions include Obese Adult Male.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04018339 | Phase 1 | Completed |
| NCT03550443 | Phase 3 | Terminated |
Competing Products
9 competing products in Obese Adult Male
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Investigational new drug company code: BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + CT-388 | Roche | Phase 2 | 52 |
| Growth hormone treatment | Pfizer | Pre-clinical | 22 |
| BMS-963272 + Placebo | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-4324 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Aleniglipron + Placebo | Structure Therapeutics | Phase 2 | 47 |
| CRB-913 + Placebo | Corbus Pharmaceuticals | Phase 1 | 25 |